Tamagno Gianluca, Federspil Giovanni, Murialdo Giovanni
Medical Clinic 3, Department of Medical and Surgical Sciences, University of Padua, Padua, Italy.
Intern Emerg Med. 2006;1(1):15-23. doi: 10.1007/BF02934715.
Encephalopathy associated with autoimmune thyroid disease, currently known as Hashimoto's encephalopathy, but also defined as corticosteroid-responsive encephalopathy associated with autoimmune thyroiditis, is a relatively rare condition observed in a small percentage of patients presenting with autoimmune thyroid disease. It consists of a subacute, relapsing-remitting, steroid-responsive encephalopathy characterised by protean neurologic and neuropsychiatric symptoms, diffuse electroencephalographic abnormalities and increased titres of antithyroid antibodies in serum and/or in cerebrospinal fluid. Most of the cases presenting this neurologic complication are affected by Hashimoto's thyroiditis or, less frequently, by other autoimmune thyroid diseases, chiefly Graves' disease. The pathogenesis of this encephalopathy is still unknown and largely debated, because of extremely varied clinical presentation, possibly referable to different aetiologic and pathophysiologic mechanisms, as confirmed by the two clinical cases we report in this paper. Autoimmune aetiology is, however, very likely in view of the well established favourable response to corticosteroid administration. Both vasculitis and autoimmunity directed against common brain-thyroid antigens represent the most probable aetiologic pathways. Clinical manifestations include consciousness changes, neurologic diffuse or focal signs, headache, and altered cognitive function. Although unspecific, cerebral oedema has also been described. Cerebrospinal fluid examination often discloses an inflammatory process, with a mild increase in protein content and occasionally in lymphocyte count. In this review, clinical criteria for the diagnosis of defined, probable, or possible encephalopathy associated with autoimmune thyroid disease are suggested. Corticosteroid therapy currently allows us to obtain rapid remission of disease symptoms, but adverse outcomes as well as spontaneous remissions have also been reported.
与自身免疫性甲状腺疾病相关的脑病,目前被称为桥本脑病,但也被定义为与自身免疫性甲状腺炎相关的皮质类固醇反应性脑病,是在一小部分患有自身免疫性甲状腺疾病的患者中观察到的相对罕见的病症。它由一种亚急性、复发-缓解型、对类固醇有反应的脑病组成,其特征为多样的神经和神经精神症状、弥漫性脑电图异常以及血清和/或脑脊液中抗甲状腺抗体滴度升高。出现这种神经并发症的大多数病例受桥本甲状腺炎影响,或较少见地受其他自身免疫性甲状腺疾病影响,主要是格雷夫斯病。由于临床表现极为多样,可能归因于不同的病因和病理生理机制,正如我们在本文中报告的两个临床病例所证实的那样,这种脑病的发病机制仍然未知且存在很大争议。然而,鉴于对皮质类固醇给药已确立的良好反应,自身免疫病因很可能存在。血管炎和针对常见脑-甲状腺抗原的自身免疫均代表最可能的病因途径。临床表现包括意识改变、神经弥漫性或局灶性体征、头痛以及认知功能改变。虽然不具有特异性,但也有脑水肿的描述。脑脊液检查常显示有炎症过程,蛋白质含量轻度增加,偶尔淋巴细胞计数也会增加。在这篇综述中,提出了诊断明确、可能或疑似与自身免疫性甲状腺疾病相关的脑病的临床标准。目前皮质类固醇疗法使我们能够迅速缓解疾病症状,但也有不良后果以及自发缓解的报道。